{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:20:04Z","timestamp":1792002004049,"version":"4.4.0"},"reference-count":79,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Acrodermatitis continua of Hallopeau (ACH) is a rare aseptic pustular dermatosis for which clinical guidelines are lacking and treatment is largely based on case reports. Biologically targeted therapies offer new therapeutic ideas, with TNF antagonists such as adalimumab showing promising efficacy in both adults and children.The IL-17 and IL-23 axes play a key role in the pathogenesis of ACH, and anti-IL-17A and anti-IL-23 antibodies have shown therapeutic efficacy. In addition, new therapies such as IL-36 inhibitors and JAK inhibitors are being explored. Although biologics provide a new direction for ACH treatment, their safety and efficacy still need to be confirmed by large-scale clinical studies.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1525821","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T05:29:16Z","timestamp":1755235756000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Acrodermatitis continua of Hallopeau: a review and update on biological and small molecule targeted immunomodulatory therapies"],"prefix":"10.3389","volume":"16","author":[{"given":"Qiong","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luyao","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhimin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanhao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhua","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuotao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.23736\/S2784-8671.21.07007-9","article-title":"Acrodermatitis continua of Hallopeau: historical perspectives and modern management","volume":"157","author":"Bhate","year":"2022","journal-title":"Ital J Dermatol Venerol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14805","article-title":"Acrodermatitis continua of Hallopeau and generalised pustular psoriasis: Should they be the same or different entities","volume":"32","author":"Chularojanamontri","year":"2023","journal-title":"Exp Dermatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2011.04993.x","article-title":"Acrodermatitis continua of Hallopeau: evolution of treatment options","volume":"50","author":"Sehgal","year":"2011","journal-title":"Int J Dermatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1177\/1203475419836435","article-title":"The use of biologic therapy in the treatment of acrodermatitis continua of hallopeau: A review","volume":"23","author":"Maliyar","year":"2019","journal-title":"J Cutan Med Surg"},{"key":"B5","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2147\/PTT.S180608","article-title":"Acrodermatitis continua of Hallopeau: clinical perspectives","volume":"9","author":"Smith","year":"2019","journal-title":"Psoriasis (Auckl)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.15041_g","article-title":"Adalimumab in drei F\u00e4llen von Anti-IL-17-refrakt\u00e4rer Acrodermatitis continua Hallopeau","volume":"21","author":"Zhang","year":"2023","journal-title":"J Dtsch Dermatol Ges"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llad333","article-title":"Paediatric acrodermatitis continua of Hallopeau: perspectives of a patient and their mother","volume":"49","author":"O'Malley","year":"2023","journal-title":"Clin Exp Dermatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13327","article-title":"A case of pediatric acrodermatitis continua of Hallopeau successfully treated with adalimumab biosimilar","volume":"33","author":"Megna","year":"2020","journal-title":"Dermatol Ther"},{"key":"B9","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.crohns.2011.08.017","article-title":"Adalimumab for a co-existing clinical condition of Crohn's disease and acrodermatitis continua of Hallopeau","volume":"5","author":"Caputo","year":"2011","journal-title":"J Crohns Colitis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2050313x19829620","DOI":"10.1177\/2050313X19829620","article-title":"Acrodermatitis continua of Hallopeau successfully treated with adalimumab: A case report","volume":"7","author":"Crowley","year":"2019","journal-title":"SAGE Open Med Case Rep"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.5152\/eurjrheum.2015.0072","article-title":"Successful treatment of Acrodermatitis continua of Hallopeau associated with psoriatic arthritis with adalimumab","volume":"2","author":"Lefkir","year":"2015","journal-title":"Eur J Rheumatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.2018.32.issue-10","article-title":"Generalized pustular psoriasis: a review and update on treatment","volume":"32","author":"Hoegler","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2006.02170.x","article-title":"Three years' experience with infliximab in recalcitrant psoriasis","volume":"31","author":"Ahmad","year":"2006","journal-title":"Clin Exp Dermatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1610-0387.2007.06332.x","article-title":"Successful etanercept therapy in therapy refractory acrodermatitis continua suppurativa Hallopeau","volume":"5","author":"Weisshaar","year":"2007","journal-title":"J Dtsch Dermatol Ges"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2007.03251.x","article-title":"Lack of efficacy of etanercept in acrodermatitis continua of Hallopeau","volume":"46","author":"Adi\u015fen","year":"2007","journal-title":"Int J Dermatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1159\/000485370","article-title":"Acrodermatitis continua of hallopeau with bone resorption in an 8-year-old patient: A case report","volume":"9","author":"Alorainy","year":"2017","journal-title":"Case Rep Dermatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14046","article-title":"Etanercept for pediatric acrodermatitis continua of Hallopeau: A case report and literature review","volume":"33","author":"Ruggiero","year":"2020","journal-title":"Dermatol Ther"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1159\/000134613","article-title":"Long-term control with etanercept (Enbrel) of a severe acrodermatitis continua of Hallopeau refractory to infliximab (Remicade)","volume":"217","author":"Thielen","year":"2008","journal-title":"Dermatology"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1159\/000519144","article-title":"Certolizumab pegol: A new therapeutic approach for acrodermatitis continua of hallopeau","volume":"8","author":"Rizzetto","year":"2022","journal-title":"Skin Appendage Disord"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2021.09.002","article-title":"Treatment and molecular profiling of acrodermatitis continua of Hallopeau during pregnancy using targeted therapy","volume":"16","author":"Al-Khawaga","year":"2021","journal-title":"JAAD Case Rep"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2019.1628170","article-title":"Treatment of acrodermatitis continua of hallopeau with ixekizumab","volume":"32","author":"Miller","year":"2021","journal-title":"J Dermatolog Treat"},{"key":"B22","first-page":"1047","article-title":"Treatment of recalcitrant acrodermatitis continua of hallopeau with brodalumab","volume":"18","author":"Milani-Nejad","year":"2019","journal-title":"J Drugs Dermatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12899","article-title":"Biologic therapy for acrodermatitis continua of Hallopeau: Successful treatment with secukinumab and review of the literature","volume":"32","author":"Galluzzo","year":"2019","journal-title":"Dermatol Ther"},{"key":"B24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/09546634.2018.1527993","article-title":"Acrodermatitis continua of Hallopeau successfully treated with secukinumab","volume":"29","author":"Balestri","year":"2018","journal-title":"J Dermatolog Treat"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2016.5059","article-title":"Secukinumab for acrodermatitis continua of hallopeau","volume":"153","author":"Muggli","year":"2017","journal-title":"JAMA Dermatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2017.02.016","article-title":"Acrodermatitis of Hallopeau and erosive oral mucositis successfully treated with secukinumab","volume":"3","author":"Baron","year":"2017","journal-title":"JAAD Case Rep"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16050","article-title":"Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3)","volume":"178","author":"Papp","year":"2018","journal-title":"Br J Dermatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15383","article-title":"Acrodermatitis continua of Hallopeau successfully treated with ixekizumab: A case report","volume":"35","author":"Battista","year":"2022","journal-title":"Dermatol Ther"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14301","article-title":"Brodalumab in the treatment of recalcitrant acrodermatitis continua of Hallopeau","volume":"33","author":"Bardazzi","year":"2020","journal-title":"Dermatol Ther"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13170","article-title":"Effectiveness of brodalumab in acrodermatitis continua of Hallopeau: A case report","volume":"33","author":"Passante","year":"2020","journal-title":"Dermatol Ther"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus secukinumab in plaque psoriasis","volume":"385","author":"Reich","year":"2021","journal-title":"N Engl J Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1001\/jamadermatol.2023.5051","article-title":"Treatment of severe palmoplantar pustular psoriasis with bimekizumab","volume":"160","author":"Passeron","year":"2024","journal-title":"JAMA Dermatol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00612-x","article-title":"Pustular psoriasis: A narrative review of recent developments in pathophysiology and therapeutic options","volume":"11","author":"Menter","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9121746","article-title":"Pustular psoriasis: from pathophysiology to treatment","volume":"9","author":"Genovese","year":"2021","journal-title":"Biomedicines"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/dth.2017.30.issue-2","article-title":"Ustekinumab for the treatment of acrodermatitis continua of Hallopeau refractory to anti-TNF agents","volume":"30","author":"Ad\u0131\u015fen","year":"2017","journal-title":"Dermatol Ther"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.1302a103","article-title":"Biologics for the treatment of severe acrodermatitis continua of hallopeau: report of two cases successfully treated with ixekizumab and ustekinumab","volume":"13","author":"Gargiulo","year":"2023","journal-title":"Dermatol Pract Concept"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S404860","article-title":"Acrodermatitis continua of hallopeau successfully treated with ustekinumab: A case report and literature review","volume":"16","author":"Shi","year":"2023","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.v34.10","article-title":"Efficacy and safety of TNF blockers and of ustekinumab in palmoplantar pustulosis and in acrodermatitis continua of Hallopeau","volume":"34","author":"Husson","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1159\/000367690","article-title":"Acrodermatitis continua of Hallopeau treated successfully with ustekinumab and acitretin after failure of tumour necrosis factor blockade and anakinra","volume":"230","author":"Saunier","year":"2015","journal-title":"Dermatology"},{"key":"B40","doi-asserted-by":"crossref","DOI":"10.1111\/ddg.13506","article-title":"Treatment of acrodermatitis continua of Hallopeau with ustekinumab as monotherapy after failure of anti-TNF agents","volume":"16","author":"Palacios-\u00c1lvarez","year":"2018","journal-title":"J Dtsch Dermatol Ges"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.3444","article-title":"Treatment of acrodermatitis continua of hallopeau with ustekinumab as monotherapy","volume":"152","author":"Cymerman","year":"2016","journal-title":"JAMA Dermatol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.5070\/D3252042897","article-title":"Acrodermatitis continua of Hallopeau response to optimized biological therapy","volume":"25","author":"Adas","year":"2019","journal-title":"Dermatol Online J"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.17036","article-title":"Local injection of micro-dose guselkumab for acrodermatitis continua of Hallopeau after failure of systemic ixekizumab treatment","volume":"63","author":"Wang","year":"2024","journal-title":"Int J Dermatol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"2229468","DOI":"10.1080\/09546634.2023.2229468","article-title":"Acrodermatitis continua of Hallopeau in an elderly patient successfully and rapidly treated with risankizumab: a case report","volume":"34","author":"Orsini","year":"2023","journal-title":"J Dermatolog Treat"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.15391","article-title":"Acrodermatitis continua Hallopeau successfully treated by risankizumab","volume":"60","author":"Hugo","year":"2021","journal-title":"Int J Dermatol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.v182.3","article-title":"Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks","volume":"182","author":"Reich","year":"2020","journal-title":"Br J Dermatol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"2050313x231180775","DOI":"10.1177\/2050313X231180775","article-title":"Successful treatment of acrodermatitis continua of Hallopeau with tildrakizumab: A case report","volume":"11","author":"Nguyen","year":"2023","journal-title":"SAGE Open Med Case Rep"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14783","article-title":"Deficiency of interleukin-36 receptor antagonist (DITRA): An analysis of 58 Chinese patients in a tertiary hospital in Taiwan","volume":"32","author":"Hsieh","year":"2023","journal-title":"Exp Dermatol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1177\/1203475419888862","article-title":"Spesolimab: A novel treatment for pustular psoriasis","volume":"24","author":"Ratnarajah","year":"2020","journal-title":"J Cutan Med Surg"},{"key":"B50","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1001\/jamadermatol.2023.6349","article-title":"Spesolimab response in a girl with acrodermatitis continua of hallopeau","volume":"160","author":"Wang","year":"2024","journal-title":"JAMA Dermatol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14824","article-title":"Efficacy of spesolimab for the treatment of generalized pustular psoriasis flares across pre-specified patient subgroups in the Effisayil 1 study","volume":"32","author":"Burden","year":"2023","journal-title":"Exp Dermatol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-022-00684-1","article-title":"Baricitinib: A review in moderate to severe atopic dermatitis","volume":"23","author":"Hoy","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3390\/ph12010037","article-title":"Baricitinib: A 2018 novel FDA-approved small molecule inhibiting janus kinases","volume":"12","author":"Mayence","year":"2019","journal-title":"Pharm (Basel)"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.0045","article-title":"Inhibition of progression of acrodermatitis continua of hallopeau with baricitinib","volume":"157","author":"Han","year":"2021","journal-title":"JAMA Dermatol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.11.060","article-title":"Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasis","volume":"90","author":"Blauvelt","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17074","article-title":"Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with moderate to severe plaque, erythrodermic, or generalized pustular psoriasis: Efficacy and safety results from an open-label, phase 3 trial","volume":"51","author":"Imafuku","year":"2024","journal-title":"J Dermatol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"2316239","DOI":"10.1080\/09546634.2024.2316239","article-title":"Successful treatment of acrodermatitis continua of Hallopeau by TYK2 inhibitor with every other day","volume":"35","author":"Kan","year":"2024","journal-title":"J Dermatolog Treat"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.5070\/D328659731","article-title":"Rapid and sustained response to apremilast in a patient with long-standing acrodermatitis continua of Hallopeau","volume":"28","author":"Fusta-Novell","year":"2022","journal-title":"Dermatol Online J"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12946","article-title":"Nails as immune-privileged sites: A case of disabling Acrodermatitis continua of Hallopeau successfully treated with Apremilast","volume":"32","author":"Lanna","year":"2019","journal-title":"Dermatol Ther"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.08.056","article-title":"IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis","volume":"140","author":"Johnston","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.12990","article-title":"Apremilast as a new treatment option for Acrodermatitis continua of Hallopeau","volume":"60","author":"Calleja Algarra","year":"2019","journal-title":"Australas J Dermatol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15423","article-title":"Acrodermatitis continua of Hallopeau: Is apremilast an efficacious treatment option","volume":"35","author":"Megna","year":"2022","journal-title":"Dermatol Ther"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.2008.00838.x","article-title":"An infant with acrodermatitis continua of Hallopeau: successful treatment with thalidomide and UVB therapy","volume":"26","author":"Kiszewski","year":"2009","journal-title":"Pediatr Dermatol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0781.2009.00468.x","article-title":"Successful treatment of a 9-year-old boy affected by acrodermatitis continua of Hallopeau with targeted ultraviolet B narrow-band phototherapy","volume":"26","author":"Bordignon","year":"2010","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2013.848259","article-title":"Acrodermatitis continua of Hallopeau (ACH): two cases successfully treated with adalimumab","volume":"25","author":"Di Costanzo","year":"2014","journal-title":"J Dermatolog Treat"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06759.x","article-title":"Successful treatment of recalcitrant acrodermatitis continua of Hallopeau with adalimumab and acitretin","volume":"153","author":"Tobin","year":"2005","journal-title":"Br J Dermatol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08893.x","article-title":"Treatment of acrodermatitis continua of Hallopeau with adalimumab","volume":"160","author":"Ryan","year":"2009","journal-title":"Br J Dermatol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1159\/000277415","article-title":"Treatment of acrodermatitis continua of Hallopeau with TNF-blocking agents: case report and review","volume":"220","author":"Puig","year":"2010","journal-title":"Dermatology"},{"key":"B69","article-title":"Acrodermatitis continua of hallopeau successfully treated with adalimumab","volume":"5","author":"Sopkovich","year":"2012","journal-title":"J Clin Aesthet Dermatol"},{"key":"B70","first-page":"887","article-title":"Adalimumab treatment of a patient with psoriasis suppurativa Hallopeau associated osteoarthropathy","volume":"27","author":"M\u00fceller","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1177\/0300060515593263","article-title":"Speckled variance optical coherence tomography for the assessment of nail involvement in acrodermatitis continua of Hallopeau: A case study","volume":"44","author":"Conti","year":"2016","journal-title":"J Int Med Res"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.2147\/BTT.S302164","article-title":"Acrodermatitis continua of hallopeau evolving into generalized pustular psoriasis following COVID-19: A case report of a successful treatment with infliximab in combination with acitretin","volume":"15","author":"Samotij","year":"2021","journal-title":"Biologics"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2008.02998.x","article-title":"Excellent and prolonged response to infliximab in a case of recalcitrant acrodermatitis continua of Hallopeau","volume":"23","author":"Rubio","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"2050313x231160937","DOI":"10.1177\/2050313X231160937","article-title":"Acrodermatitis continua of Hallopeau successfully treated with bimekizumab: A case report","volume":"11","author":"Cirone","year":"2023","journal-title":"SAGE Open Med Case Rep"},{"key":"B75","doi-asserted-by":"publisher","first-page":"234","DOI":"10.4103\/ijd.ijd_884_22","article-title":"Ixekizumab for the treatment of acrodermatitis continua of hallopeau and inverse psoriasis","volume":"68","author":"Xia","year":"2023","journal-title":"Indian J Dermatol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.2019.17.issue-6","article-title":"Two cases of acrodermatitis continua suppurativa (Hallopeau's disease) treated with IL-17A inhibitors","volume":"17","author":"Schmid","year":"2019","journal-title":"J Dtsch Dermatol Ges"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.v19.10","article-title":"Successful therapy of acrodermatitis continua of Hallopeau with IL-23 blockers -two new cases","volume":"19","author":"Langer","year":"2021","journal-title":"J Dtsch Dermatol Ges"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1338285","article-title":"Successful treatment of acrodermatitis continua of Hallopeau coexisting with generalized pustular psoriasis with spesolimab: a case report","volume":"15","author":"Wen","year":"2024","journal-title":"Front Immunol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14927","article-title":"Successful treatment of acrodermatitis continua of Hallopeau with apremilast","volume":"46","author":"Kurihara","year":"2019","journal-title":"J Dermatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1525821\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T05:29:18Z","timestamp":1755235758000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1525821\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,15]]},"references-count":79,"alternative-id":["10.3389\/fimmu.2025.1525821"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1525821","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,15]]},"article-number":"1525821"}}